# SBRT + Atezolizumab + Bevacizumab in Resectable HCC

> **NCT04857684** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Resectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **RADIATION:** Stereotactic Beam Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT04857684
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-18
- **Primary completion:** 2026-04-29
- **Final completion:** 2027-04-29
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857684, "SBRT + Atezolizumab + Bevacizumab in Resectable HCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04857684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*